Hong Kong stocks rebounded again, with pharmaceutical stocks rising, and the industry's investment and financing are expected to hit bottom and rebound. The release of innovative drug policies has provided bullish signals.

According to the Zhongtong Finance APP, pharmaceutical stocks have risen again. As of press time, Kexing Biotech-B (06990) rose 9.07%, reporting HKD 155.1; Zai Lab (09688) rose 4.63%, reporting HKD 14.02; Genscript Biotech (01548) rose 4.59%, reporting HKD 10.02; and Innocare (09969) rose 4.57%, reporting HKD 5.03. On the news front, the US June CPI slowed down more than expected, pushing the probability of a rate cut in September to nearly 90%. Pacific Securities pointed out that as the Fed's rate hike cycle comes to an end in the future, liquidity is expected to gradually ease.

Zhitong Finance21:56 ET

Innocare (09969) granted 2.79 million restricted stock units.

Innocare (09969) announced on June 28, 2024 that the company had implemented a stock-based incentive plan for 2023.

Zhitong FinanceJun 28 06:40 ET

Hong Kong stocks surged | Innocare (09969) rose more than 4%, and the company's tumor products are steadily expanding their indications. Recently announced the highest to receive 3 billion yuan of financial management.

Innocare (09969) rose more than 4%. As of the time of publication, it has risen 4.3%, with a price of HKD 4.85 and a turnover of HKD 8.87 million.

Zhitong FinanceJun 27 23:57 ET

Innocare (09969) plans to use up to 3 billion yuan of idle self-owned funds for money market management.

Innocare (09969) announced its intention to use its own unused capital of not more than RMB 3 billion to purchase ...

Zhitong FinanceJun 25 08:30 ET

Innocare (09969): The first vesting condition of the 2023 Star Market restricted stock incentive plan has been achieved, and about 1.6348 million shares are expected to vest.

Innocare (09969) announced that according to the Measures for the Administration of Stock-based Incentives of Listed Companies and the Science and Technology Innovation Board in 2023...

Zhitong FinanceJun 25 07:30 ET

Does InnoCare Pharma (HKG:9969) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like

Simply Wall StJun 21 20:03 ET